NCGS Incorporated Selects Merge eClinical OS(TM) for Phase I-IV Studies
Solution Provides Anywhere, Anytime Access to Comprehensive Set of Clinical
CHICAGO, Dec. 4, 2012 (GLOBE NEWSWIRE) -- Merge Healthcare Incorporated
(Nasdaq:MRGE), a leading provider of clinical systems and innovations that
seek to transform healthcare, today announced that NCGS Incorporated has
selected Merge's eClinical OS™ and clinical trial management (CTMS) solution
to streamline data management activity through electronic data capture (EDC)
technology transfer and improve study management efficiency.
Merge Healthcare Logo
NCGS focuses on complex areas of clinical development, such as
oncology-hematology, infectious disease, critical care and CNS. As a single,
web-based solution, Merge eClinical OS has the flexibility to support trials
in any phase. NCGS has implemented Merge's solutions across all therapeutic
areas and Phase I-IV studies.
"Initially NCGS used a competitive product in-house for data management needs.
Later data management was moved externally and outsourced to a third party.
The latter was a cumbersome process," said Nancy C. G. Snowden, CEO of NCGS
Incorporated. "With eClinical OS, we saw the opportunity to bring EDC back
in-house. Managing data in-house and utilizing the build tools eClinical OS
provides, shortens study deployment timelines, provides NCGS and our clients
complete control of clinical data with real time access, provides a
competitively priced solution and shortens timelines to datalock. The
self-service quoting tool, the Configurator, allows NCGS to quickly estimate
study costs and generate quotes for our clients."
"Most EDC systems are developed solely from a data manager perspective;
however, many organizations need a solution for all user groups," said Justin
Dearborn, President of Merge Healthcare. "Merge eClinical OS is designed to
help clients build, deploy, manage and run studies faster and more cost
effectively, with little technical background required."
"We were pleased to find that eClinical OS houses such a comprehensive set of
capabilities. Using one system for randomization, patient reported outcomes,
medical coding, and practically anything else that a particular study could
call for creates operational and quality efficiencies," continued Snowden.
"NCGS has also partnered with Merge for our clinical trial management system
(CTMS) requirements, which will maximize efficiency across all our studies.
Access to regulatory documentation and operation data via the CTMS provides
our clients with moment to moment updates and status reporting through
Merge eClinical OS provides end-to-end study support through a single,
easy-to-use interface allowing clients to manage and run studies more
efficiently than ever before. It delivers built-in study templates, libraries
and reports to help users create studies quickly and manage them effectively
without technical assistance. Merge eClinical OS works for the largest and
smallest studies, has the flexibility to support trials in any phase, and
captures any type of data, from any source, from any modality.
About Merge Healthcare
Merge is a leading provider of clinical systems and innovations that seek to
transform healthcare. Merge's enterprise and cloud-based solutions for image
intensive specialties provide access to any image, anywhere, any time. Merge
also provides health stations, clinical trials software and other health data
and analytics solutions that engage consumers in their personal health. With
solutions that are used by providers and consumers and include more than 20
years of innovation, Merge is helping to reduce costs and improve the quality
of healthcare worldwide. For more information, visit merge.com.
The Merge Healthcare logo is available at
About NCGS Incorporated
NCGS Incorporated is a full-service Contract Research Organization (CRO)
focusing on complex areas of clinical development; oncology-hematology,
infectious disease, critical care and CNS in both adult and pediatric
populations. In 28 years of operation, NCGS has worked on the approval or
expanded approval of 28 drug, biologic, diagnostic and device products and has
had no FDA Warning Letters / 483s. For more information, visit ncgs.com.
The NCGS Incorporated logo is available at
Cautionary Notice Regarding Forward-Looking Statements
The matters discussed in this news release may include forward-looking
statements, which could involve a number of risks and uncertainties. When used
in this press release, the words "will," "believes," "intends," "anticipates,"
"expects" and similar expressions are intended to identify forward-looking
statements. Actual results could differ materially from those expressed in, or
implied by, such forward-looking statements. Except as expressly required by
the federal securities laws, the Company undertakes no obligation to update
such factors or to publicly announce the results of any of the forward-looking
CONTACT: Media Contacts:
Vice President, Marketing,
Director, Strategic Sourcing and
Recruitment, NCGS Incorporated
Merge Healthcare Logo
Press spacebar to pause and continue. Press esc to stop.